Natera, Inc. (NTRA) Stock: Price, Forecast & Analyst Target
Natera, Inc. (NTRA) — MoonshotScore 36/100 (Weak band), calculated Nov 18, 2026. Price $289.50 (+0.71%), as of the Nov 18, 2026 trading session; market cap $42.0B.
Educational signal · not a buy or sell recommendation · How to read this
Natera, Inc. · NTRA · NASDAQ · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-12: Natera sells molecular tests used in reproductive health, cancer surveillance, and transplant monitoring, with product testing rather than licensing providing nearly all revenue. Rapid product-revenue expansion is now producing operating cash, yet accounting losses persist as research and commercial spending climbs; durable operating leverage remains the unresolved test.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Natera (NTRA)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a strained balance sheet — yet price is running hot, well ahead of those stalled fundamentals; treat the move with suspicion, not chase. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Strained; Valuation: Rich; Growth Durability: Growing; Momentum: Surging.
- EPS beat 3 of the last 8 reports
- Altman Z 28.32 · Piotroski F 2
- ROE -10.6% · ROA -6.8% · current ratio 2.81
Holding back: balance-sheet strain
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 38 | Weak | |
| 37 | Weak | |
| 37 | Weak | |
| 37 | Weak | |
| 36 | Weak | |
| 36 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $289.50 | |
| Change on the day | +0.71% | |
| 52-week range | $181.00–$437.41 | |
| Market capitalisation | $42.0B | — |
| Shares traded on the day | 1.96M | |
| Beta (volatility vs the S&P 500) | 1.52 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Natera (NTRA): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Natera (NTRA), and what does it report?
Short answer · as of
Natera is a testing-services business, not an instrument vendor or drug developer. Panorama and Horizon address reproductive decisions, Signatera analyzes circulating tumor DNA in oncology, and Prospera monitors organ rejection.
Research dated 2026-09-12.
Reported revenue overwhelmingly reflects product activity, while licensing and other revenue is small. Constellation extends the model by giving laboratory clients access to proprietary algorithms and bioinformatics so they can validate and launch tests themselves; distribution combines direct sales with laboratory and distribution partners.
What do the latest results show for Natera (NTRA)?
Research dated 2026-09-12.
Revenue advanced throughout the displayed quarterly series and reached a new series high in the latest period. Gross profit rose with it, while operating and net losses narrowed from the preceding period but remained material. Research spending increased again as selling, general and administrative expense was roughly steady.
Reported revenue exceeded the contemporaneous estimate in every earnings observation shown, yet the income statement still records losses in most periods. Positive operating cash flow shows that growth is translating into cash from operations, although the latest capital spending absorbed more cash than operations produced.
Management’s forward statement concerns a planned commercial launch contingent on final pricing and reimbursement determination. That is a future commercialization milestone, not an explanation for the latest revenue increase.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $592M | -$88M | -$0.64 (diluted) |
| Q4 FY2025 | $665M | $47M | — |
| Q1 FY2026 | $697M | -$85M | -$0.60 (diluted) |
| Q2 FY2026 | $753M | -$67M | -$0.47 (diluted) |
What are the financial strengths and risks for Natera (NTRA)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Cash and short-term investments exceed debt by a wide margin and also exceed total liabilities, while the cash balance has risen across the displayed history. Operating cash flow was positive in every shown quarter.
That protection should not be confused with mature profitability. Trailing margins remain negative, the latest period still carried operating and net losses, and research spending is climbing; capital spending also exceeded operating cash inflow in the latest quarter. If test revenue slows while those costs stay elevated, the route from gross profit to durable free cash flow becomes harder.
Valuation magnifies execution risk: sales and book multiples are elevated, while free cash flow yield is thin and net cash is modest beside market value. The balance sheet can absorb setbacks, but it cannot by itself justify the equity value.
Data-derived red flags
- Negative return on equity (-10.6%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Natera (NTRA)?
Short answer · as of
Current published price targets run low $245.00 · high $500.00 · consensus $393.16 · median $407.50 against a quoted price of $289.50 (as of Nov 18, 2026).
Research dated 2026-09-12.
The next earnings expectation calls for revenue below the latest reported level even as the expected loss per share narrows. Watch whether product-test revenue holds its trajectory, gross profit grows faster than research and commercial costs, and operating cash flow again exceeds capital spending.
Commercially, the named checkpoint is final pricing and reimbursement determination for the planned launch. Confirmation would be launch progress paired with product revenue and cash conversion; slippage or weak economics would leave the current spending ramp carrying more of the burden.
Longer-range consensus assumes continued revenue expansion and eventual positive earnings, while current multiples already reflect substantial expectations. The useful comparison is not merely against consensus revenue; it is whether loss contraction becomes repeatable rather than appearing intermittently.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Natera compare with its peers?
Short answer
Natera's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Natera differs through the combination of reproductive testing, circulating-tumor-DNA surveillance, transplant monitoring, and a cloud platform that lets laboratory clients use its algorithms. This is not a licensing-led genomics model: reported revenue is overwhelmingly product revenue, so adoption and utilization of Natera’s tests matter far more than software fees.
That mix provides several routes to clinical demand without changing the core engine: molecular tests distributed directly and through laboratory partners. Breadth does not remove the need for product testing to fund a large research and sales base.
| Company | Price | Market value | Score |
|---|---|---|---|
| $698.47 Nov 18, 2026 | $55.0B | 96 5-pillar Nov 18, 2026 | |
| $82.52 Nov 18, 2026 | $30.8B | 93 5-pillar Nov 18, 2026 | |
| $1737.26 Nov 18, 2026 | $34.6B | 93 5-pillar Nov 18, 2026 | |
| $646.87 Nov 18, 2026 | $18.1B | 92 5-pillar Nov 18, 2026 | |
| $210.01 Nov 18, 2026 | $31.8B | 84 5-pillar Nov 18, 2026 | |
| $177.33 Nov 18, 2026 | $50.0B | 83 5-pillar Nov 18, 2026 | |
| $29.81 Nov 18, 2026 | $29.1B | 78 5-pillar Nov 18, 2026 | |
| $259.52 Nov 18, 2026 | $28.6B | 74 5-pillar Nov 18, 2026 | |
| $257.84 Nov 18, 2026 | $42.5B | 71 5-pillar Nov 18, 2026 | |
| $370.78 Nov 18, 2026 | $30.1B | 71 5-pillar Nov 18, 2026 | |
| $152.43 Nov 18, 2026 | $17.0B | 71 5-pillar Nov 18, 2026 | |
| $333.25 Nov 18, 2026 | $16.0B | 70 5-pillar Nov 18, 2026 | |
| Natera (NTRA) — this page | $289.50 | $42.0B | 36 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $245.00 – $500.00
- Consensus target
- $393.16
- Median target
- $407.50
Consensus record · Captured .
Measured against a quoted price of $289.50 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 11, 2026
- Transactions
- 60
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 60
- Other transactions
- 0
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held NTRA in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 29.22% | $1.31B | Trimmed −0.8% shares |
| Coatue | Philippe Laffont | Q3 2026 | 1.84% | $1.00B | Trimmed −3.0% shares |
| ARK Invest | Cathie Wood | Q3 2026 | 1.30% | $225.73M | Trimmed −20.7% shares |
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.05% | $11.01M | Added +334.2% shares |
| Viking Global | Andreas Halvorsen | Q3 2026 | 0% | $0 | Sold out (was $106.05M) |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Natera (NTRA)?
Natera Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does Signatera differ from Panorama in Natera’s portfolio?
Panorama screens a pregnancy for fetal chromosomal abnormalities from maternal blood, while Signatera uses circulating tumor DNA in cancer-related testing. They address distinct clinical settings but feed the same product-led testing model.
Why does Constellation matter when Natera is a product-testing company?
Constellation lets laboratory clients use Natera’s algorithms and bioinformatics to validate and launch their own tests. It broadens access to the company’s technology, although licensing and other revenue remains small beside product revenue.
Can Natera keep funding Signatera and reproductive testing while reporting losses?
Net cash and positive operating cash flow across the displayed quarters provide meaningful funding capacity. Rising research expense, negative margins, and a latest period in which capital spending exceeded operating inflow make cash conversion the constraint to watch.
What stands between Natera and its planned commercial launch?
Final pricing and reimbursement determination is the stated condition, and management described that work as on track. Subsequent product revenue and cash conversion would show whether the launch is economically meaningful.
What is the NTRA stock price today?
The last price recorded for Natera, Inc. (NTRA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the NTRA price target?
The analyst consensus price target for Natera, Inc. (NTRA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold NTRA
Funds in our ETF coverage that list NTRA among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Global X - Genomics & Biotechnology ETF (GNOM) | 3.91% | |
| WisdomTree BioRevolution Fund (WDNA) | 2.44% | |
| iShares Morningstar Small-Cap Growth ETF (JKK) | 0.95% |